Clinical trial
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have…
NCT00109096 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00109096 |
|---|---|
| Title | Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy |
| Official title | A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 100 |
| Start date | Jun 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Apr 25, 2005 |
| Last update posted | May 17, 2007 |
| Countries | Belgium, Germany, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: